Case: A 16-month-old female presented to a referring emergency department with a 2-day history of a progressive rash and swelling that started on her right lower extremity and spread to her upper extremities, trunk, and face (Fig 1) . The patient had recently been hospitalized at the referring hospital for bronchiolitis caused by respiratory syncytial virus and was being treated with amoxicillin for otitis media. Her mother had stopped the antibiotic 1 day before presentation after development of a rash and had given the patient diphenhydramine, with no improvement. The patient had a fever with the preceding illness but on admission to the emergency department was afebrile. She had received hepatitis B and diphtheria-tetanus-acellular pertussis vaccines at her 15-month well-child examination 3 weeks before the onset of the rash. The patient had 1 day of decreased oral intake and decreased urine output and a 2-day history of loose stools. Family history is signifi cant for multiple maternal family members with reaction to penicillin causing hives and edema. At the referring hospital, intraosseous (IO) access was obtained after multiple attempts to place intravascular access were unsuccessful, secondary to diffuse body edema. In our emergency department, the medical team attempted to obtain intravascular access with ultrasound guidance; however, they were also unsuccessful because of the patient's persistent edema. The patient received normal saline via the IO line in addition to oral acetaminophen and diphenhydramine.
HOSPITAL Pediatrics

®
AN OFFICIAL JOURNAL OF THE AMERICAN ACADEMY OF PEDIATRICS
Question: What is AHEI and how can it be differentiated from other targetoid rashes such as erythema multiforme (EM), urticaria, or fi xed drug reaction?
Discussion: AHEI is an uncommon, self-limiting acute cutaneous vasculitis that was fi rst described by Snow in 1913 . 1 Nearly 100 years later, Blasini et al 2 described AHEI as a rare, benign acute cutaneous vasculitis that occurs between 4 and 24 months of age. The authors concur with Snow that the disease is self-limiting and further characterize it as edematous purpuric plaques on the extremities, the acute appearance of edema, and fever. AHEI is more commonly reported in the winter season, and illness duration is 5 to 35 days. 3, 4 Bacterial or viral infections, medications, and immunizations have all been recognized as possible contributors to the onset of AHEI. 4, 5 It is reported in all areas of the world with no racial predominance.
Due to its vasculitic nature and appearance, AHEI has been suggested as a variant of Henoch-Schönlein purpura (HSP), a more well-known clinical entity. Saraclar et al 3 compared the clinical, serologic, and immunohistologic fi ndings of 12 patients with AHEI versus the expected fi ndings in HSP. Although the histopathologic fi ndings were similar, the immunohistologic pattern found in this series of patients was a different pattern from HSP. They concluded that AHEI should be considered as a separate, clinicopathologic entity or a possible variant of HSP. Clinically, HSP occurs in older children, the lesions are characteristically on the lower extremities, and patients have the potential for multiorgan complications. Considering its clinical features, AHEI was characterized by da Silva Manzoni et al 6 as a unique disorder, distinct from HSP.
In addition to making a distinction between AHEI and HSP, other diagnoses such as urticaria, EM, and fi xed drug reaction should be considered when a child presents with erythematous annular lesions. Urticaria has the typical pruritic and erythematous undulating plaques similar to AHEI; however, the central area of duskiness is typically lacking. In addition, urticarial lesions are transient and often resolve with oral diphenhydramine. EM typically manifests as a target lesion with 3 distinct areas whereas AHEI usually contains 2 areas. 7 The characteristic EM targetoid lesion has a central area of erythema or purpura that may be dusky (similar to AHEI), a middle lighter colored area (lacking in AHEI), and an outer zone of erythema completing a concentric target. EM lesions are normally fi xed, symmetric, and pruritic. In addition, EM may have predominant mucosal involvement, which is not seen with AHEI. A fi xed drug reaction, although it may appear very similar to AHEI, is typically limited to a few lesions. A fi xed drug reaction with more than a few lesions will typically only occur after multiple exposures, and it is not associated with systemic symptoms. AHEI has associated edema of hands, feet, or face/ears that is not characteristic of urticaria, EM, or fi xed drug reaction.
CASE CONTINUATION:
The rash and edema progressed to involve more body surface area within hours of admission, and the patient refused all fl uids by mouth. The ecchymotic lesions on her trunk and upper extremities increased in size. Because her left lower extremity was more edematous compared with the right, a radiograph was obtained and confi rmed IO catheter infi ltration. The IO line was removed, and a nasogastric tube was placed to provide maintenance fl uids. The patient continued on hydroxyzine (1 mg/kg per dose) and diphenhydramine (1 mg/kg per dose) orally every 6 hours without clinical improvement. On hospital day 2, she was started on prednisolone 2 mg/kg per day. Within 12 hours of receiving corticosteroids, her edema and ecchymosis decreased. She remained on oral steroids for the remainder of her hospitalization, and her rash, edema, and pruritus continued to decrease daily until the day of discharge. In total, she completed 5 days of prednisolone (2 mg/kg per day) and 5 days of ranitidine (1 mg/kg per dose, twice daily). 
Question: What treatment regimens have been successful at reducing symptoms in AHEI?
Discussion: Historically, the treatment of AHEI has been limited to supportive care such as antihistamines for pruritus and analgesics for discomfort. Saraclar et al 3 described 12 infants with AHEI who were all administered antihistamines and who had complete resolution in 5 to 11 days. Acun et al 4 concurred that spontaneous, complete resolution without complications usually occurs within 5 to 14 days, but the disease may endure as long as 35 days. da Silva Manzoni et al, 6 however, describe the case of a 9-month-old male with AHEI treated with corticosteroids. The administration of corticosteroids was an attempt to avoid rapid progression of the disease, as the patient had acute, rapidly expanding and profuse cutaneous lesions. In contrast to the literature, there was clear improvement 24 hours after the onset of the disease once the prednisolone therapy was started. As soon as administration of the medication was discontinued, there was a quick relapse followed by improvement when it was re-administered.
CONCLUSIONS:
Our patient had AHEI that involved a large percentage of her surface area, caused discomfort, and prevented her from maintaining appropriate hydration without medical intervention. Although steroids are not routinely recommended in the treatment of AHEI, our patient appeared to benefi t from this medical therapy. It may be reasonable to consider corticosteroids when caring for a patient with severe AHEI.
Learning Points:
1. AHEI has a broad differential diagnosis and can vary in severity upon clinical presentation. 2. AHEI has historically been treated symptomatically with spontaneous resolution.
3. There may be an indication in severe AHEI requiring hospitalization for treatment with steroids.
